COMPARISON OF A NEW ANORECTIC AGENT AN 448 WITH FENFLURAMINE IN THE TREATMENT OF REFRACTORY OBESITY

Abstract
The efficacy and safety of a new synthetic tricyclic anorectic agent, AN 448, were tested against fenfluramine in a single‐blind crossover trial on 22 severely obese patients. AN 448 exhibited an equivalent anorectic effect to that of fenfluramine. Both drugs were well tolerated and caused no serious side effects. However, a progressive resistance developed to the anorectic effects of AN 448 and fenfluramine so limiting their long‐term usefulness in the treatment of refractory obesity.